These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 13730105)

  • 1. Fibrinolysis and fibrinogenemia in carcinoma of the lung.
    O'NEILL JJ; EVANS TS
    Conn Med; 1961 Mar; 25():158-61. PubMed ID: 13730105
    [No Abstract]   [Full Text] [Related]  

  • 2. [Determination of fibrinogen and fibrinolytic activity of the blood in lung cancer, chronic non-specific pneumonia and exudative pleuritis].
    Voprontsova GV
    Sov Med; 1967 May; 30(5):14-7. PubMed ID: 5612340
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of stressing stimuli on fibrinogen, hematic fibrinolysis and production of pulmonary metastases].
    Agostino D
    Osp Ital Chir; 1967 Feb; 16(2):141-6. PubMed ID: 5601235
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
    Hataji O; Taguchi O; Gabazza EC; Yuda H; D'Alessandro-Gabazza CN; Fujimoto H; Nishii Y; Hayashi T; Suzuki K; Adachi Y
    Am J Hematol; 2004 Jul; 76(3):214-9. PubMed ID: 15224354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasma D-dimer level is associated with decreased survival in patients with lung cancer.
    Altiay G; Ciftci A; Demir M; Kocak Z; Sut N; Tabakoglu E; Hatipoglu ON; Caglar T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):494-8. PubMed ID: 17513096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the results of the Brdicka reaction with fibrinogen level and fibrinolysis of plasma euglubolins for the diagnosis of malignant neoplasms].
    Kosmala U; Niewiadomska S; Plamieniak Z
    Pol Tyg Lek; 1969 Jul; 24(29):1112-5. PubMed ID: 5808598
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate.
    Collet JP; Nagaswami C; Farrell DH; Montalescot G; Weisel JW
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):382-6. PubMed ID: 14656741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis; report of a case and clinical review.
    COHEN SN; KUPFER HG
    N Engl J Med; 1958 Dec; 259(23):1103-7. PubMed ID: 13600632
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer.
    Jones JM; McGonigle NC; McAnespie M; Cran GW; Graham AN
    Lung Cancer; 2006 Jul; 53(1):97-101. PubMed ID: 16698114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in the content of fibrinogen and corticosteroids in the blood during the development of experimental lung cancer in rats].
    Negrei LM; Sopotsins'ka OB; Balenko NV; Smelkova MI
    Fiziol Zh; 1973; 19(4):530-3. PubMed ID: 4769289
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.
    Guadagni F; Ferroni P; Basili S; Facciolo F; Carlini S; Crecco M; Martini F; Spila A; D'Alessandro R; Aloe S; Cerasoli V; Del Monte G; Mariotti S; Mineo TC; Roselli M
    Lung Cancer; 2004 Jun; 44(3):303-10. PubMed ID: 15140543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels.
    Smith JD; Chen A; Ernst LA; Waggoner AS; Campbell PG
    Bioconjug Chem; 2007; 18(3):695-701. PubMed ID: 17432824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycolaldehyde induces fibrinogen post-translational modification, delay in clotting and resistance to enzymatic digestion.
    Andrades ME; Lorenzi R; Berger M; GuimarĂ£es JA; Moreira JC; Dal-Pizzol F
    Chem Biol Interact; 2009 Aug; 180(3):478-84. PubMed ID: 19397901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two families of synthetic peptides that enhance fibrin turbidity and delay fibrinolysis by different mechanisms.
    Pandi L; Kollman JM; Lopez-Lira F; Burrows JM; Riley M; Doolittle RF
    Biochemistry; 2009 Aug; 48(30):7201-8. PubMed ID: 19588915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The COOH-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth.
    Akakura N; Hoogland C; Takada YK; Saegusa J; Ye X; Liu FT; Cheung AT; Takada Y
    Cancer Res; 2006 Oct; 66(19):9691-7. PubMed ID: 17018627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
    Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
    J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1.
    Thelwell C; Longstaff C
    J Thromb Haemost; 2007 Apr; 5(4):804-11. PubMed ID: 17408411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrochemical processing of fibrinogen modified-graphite surfaces: effect on plasmin generation from adsorbed plasminogen.
    Alfonsi-Hourdin S; Longchamp S; Gallet O; Nigretto JM
    Biomaterials; 2006 Jan; 27(1):52-60. PubMed ID: 16029886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIBRINOLYSIS IN PATIENTS WITH PROSTATIC CANCER.
    ANDERSSON L
    Acta Chir Scand; 1963; 126():172-83. PubMed ID: 14059865
    [No Abstract]   [Full Text] [Related]  

  • 20. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.